Literature DB >> 9193290

Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease.

T J Fletcher1, W S Tunnicliffe, K Hammond, K Roberts, J G Ayres.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9193290      PMCID： PMC2126836          DOI： 10.1136/bmj.314.7095.1663

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

Review 1.  Influenza vaccinations: who needs them and when?

Authors:  Eelko Hak; Arno W Hoes; Theo J M Verheij
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries.

Authors:  S M A A Evers; A J H A Ament; G L Colombo; H B Konradsen; R R Reinert; D Sauerland; K Wittrup-Jensen; C Loiseau; D S Fedson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

Review 3.  Vaccines for preventing pneumococcal infection in adults.

Authors:  Sarah Moberley; John Holden; David Paul Tatham; Ross M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 4.  Influenza vaccines for preventing cardiovascular disease.

Authors:  Christine Clar; Zainab Oseni; Nadine Flowers; Maryam Keshtkar-Jahromi; Karen Rees
Journal:  Cochrane Database Syst Rev       Date:  2015-05-05

5.  Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly.

Authors:  Yu Bin Seo; Won Suk Choi; Jacob Lee; Joon Young Song; Hee Jin Cheong; Woo Joo Kim
Journal:  Clin Exp Vaccine Res       Date:  2017-01-25

6.  Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.

Authors:  Kei Nakashima; Masahiro Aoshima; Satoko Ohfuji; Satoshi Yamawaki; Masahiro Nemoto; Shinya Hasegawa; Satoshi Noma; Masafumi Misawa; Naoto Hosokawa; Makito Yaegashi; Yoshihito Otsuka
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.